Learn More
2514 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that forms perivascular tracks and promotes endothelial cell(More)
PURPOSE This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl(More)
2614 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that promotes endothelial cell adhesion, survival and(More)
2539 Background: DCE-MRI allows for the functional analysis of tumor microcirculation and composition, and has been used to evaluate changes in vascular parameters in response to anti-angiogenic(More)
2586 Background: Monoclonal antibody therapeutics in oncology are most frequently dosed using body weight (BW)-based dosing, which may be due to the perception that BW-based dosing may be more(More)
PURPOSE Therapeutic strategies to enhance the efficacy of radioimmunotherapy have not been explored. Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and(More)
  • 1